DARMSTADT, Germany, January 24, 2019 /PRNewswire/ — Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editin
Source: www.prnewswire.com
Merck KGaA has inked an exclusive licensing agreement with Vertex Pharmaceuticals Inc. for two DNA-dependent protein kinase (DNA-PK) inhibitors. These include M9831, and an additional pre-clinical compound – in the field of gene editing for six specific genetic disease indications. As per the terms, Merck KGaA would receive an upfront payment in addition to milestones and royalties on future net sales. Merck KGaA also retains the rights to both assets in all other disease areas, including oncology, with the ability to develop both these compounds in-house, or to license them to future partners in the gene editing field, while Vertex has the option to add indications to the license grant.
